In gliomas (n = 4) from patients with MUTYH, PMS2, or POLE GVs, the median TMB was elevated (7.28, range: 6.02–8.59 mutations per megabase, Supplementary Table 2b online resource) compared to that previously defined for gliomas (2.6 mutations per megabase) [78]. This evidence concerns the gene PMS2 and central nervous system cancer.